Post-Transplant Patient Care Startup Acrannolife Genomics Expecting The Revenue of ₹4000 Crores After Shark Tank India

Acrannolife Genomics, an innovative company focused on post-transplant patient care, has launched a revolutionary tool called Trunome. This non-invasive diagnostic solution is designed to detect diseases early and monitor them through a straightforward blood test. Trunome is notable for being the first of its kind in Asia and has been developed entirely in India, with US patents in place to protect the technology.

Click here to visit their official website: Acrannolife

The company has conducted tests on over 5,000 samples, positively affecting more than 1,500 patients to date. Priced at approximately $500 in India (around ₹41,000), Trunome is significantly more affordable compared to its competitors, who charge about ₹2.5 lakhs for similar services. The company is backed by three prominent doctors who are shareholders. They have also achieved clearance from the CDSCO for their facility.

Related: Pharmaceuticals Startup Pharmallama with Smart Pill Boxes and ₹2 crores for 5% Equity Shark Tank Deal!

Agragesh Ramani and Avinash Ramani are the founders of a company called Trunome. Avinash has a strong scientific background, having earned a PhD in monocular biology. On the other hand, Agragesh has completed his MBA from IMT Ghaziabad. He serves as the CEO of the company.

Currently, Acrannolife Genomics is collaborating with five major transplant hospitals in the country and has secured contracts from six hospitals in India, with confirmed orders in place. For the fiscal year 2021-2022, the company’s revenue reached ₹5 Crores, and they anticipate exceeding ₹10 Crores for the fiscal year 2022-2023. Their monthly revenue from Trunome is around ₹35 Lakhs, with an EBITA of about ₹10 Lakhs. Recently, they completed another funding round just a month and a half before their pitch, which valued the company at ₹75 Crores. Looking ahead, they have ambitious goals, aiming for revenue of ₹4,000 Crores.

Namita, one of the investors, felt that the founders were not well-prepared and lacked a clear understanding of their market, leading her to withdraw from the deal as she believed the market in India wasn’t large enough. Peyush offered ₹1.5 Crores for a 2% share in the company, while Anupam made a similar offer but for a slightly smaller 1.75% stake. Vineeta proposed ₹75 lakhs for 1% equity, along with interest-free debt for the remaining amount. The founders then asked if the interested sharks could join forces for a single investment. In the end, the sharks came together and made a unified offer of ₹1.5 Crores for a 2% stake, which the founders accepted without hesitation.

After the show, it was found that the company did not finalize a deal with any of the investors. The reasons for this are not clear. Despite this setback, the company is still operating and is doing well as of December 2023. They even announced on LinkedIn that they have become the top biotech startup in Chennai, which is a city in India.